Cancer Drug Parity Act of 2025
Summary
HR4101 (Cancer Drug Parity Act) was introduced in the House and referred to committee in June 2025. It mandates equal cost-sharing for oral and intravenous anticancer drugs in group health plans. At this early legislative stage with no committee action or companion bill, the market impact is negligible. Targeted pharmaceutical companies with oral oncology portfolios could benefit if the bill advances, but passage is highly uncertain.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR4101 is in early procedural stage with no committee action in 10 months — near-zero near-term market impact.
- 2.Bill imposes a private market mandate, not government spending — no direct taxpayer funding authorized.
- 3.If enacted, oral oncology drugmakers (MRK, BMY, LLY) benefit from increased patient access; infused drug competitors see neutral-to-negative effects.
- 4.Passage probability low absent Senate companion bill or committee momentum.
Market Implications
At current stage, this bill drives zero measurable market movement. MRK at $108.85 (down 9.51% in 30 days), BMY at $57.69 (down 4.88%), and LLY at $904.48 (down 1.66%) all reflect existing fundamentals, not legislative anticipation. Investors should monitor Committee on Education and Workforce actions — any markup or hearing would represent a material positive catalyst for oral oncology names. Until then, this bill is background noise for pharma portfolios.
Full Analysis
HR4101, the Cancer Drug Parity Act of 2025, was introduced in the House on June 24, 2025, by Rep. Grothman (R-WI) with 27 cosponsors. The bill was referred to the House Committee on Education and Workforce, where it has remained without further action for approximately 10 months. This is a standard early-stage procedural posture.
The bill statutorily mandates that group health plans subject to ERISA must provide cost-sharing for oral anticancer drugs on terms no less favorable than for intravenous or injected anticancer drugs. There is no authorized funding amount — the bill imposes a regulatory mandate on private insurers and employers, not a government spending program. The Congressional Budget Office would score this as potential premium changes, not direct federal outlays.
Structural winners are pharmaceutical companies with significant oral oncology product lines. Key beneficiaries include Merck ($MRK) with Lynparza and other oral oncolytics, Bristol-Myers Squibb ($BMY) with Pomalyst, Revlimid, and Inrebic, and Eli Lilly ($LLY) with pirtobrutinib. Companies primarily focused on infused biologics (e.g., certain products at $AMGN, $PFE) could face neutral-to-slightly-negative competitive pressure as oral alternatives gain cost parity.
Real market data for these tickers shows broad pharmaceutical sector weakness over the past 30 days: MRK down 9.51%, BMY down 4.88%, LLY down 1.66%. These moves reflect broader market trends and company-specific factors (MRK's Keytruda patent cliff concerns, BMY's patent expirations) — not this bill, which has minimal market attention given its procedural status.
Legislative path: the bill must pass the House Education and Workforce Committee, then the full House, then the Senate, then be signed by the President. No Senate companion bill exists. With only 27 cosponsors and no recorded committee markup in 10 months, passage odds are below 10%. The 119th Congress runs through January 2027, so the bill retains viability through that window.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Mandate for group health plans to equalize cost-sharing between oral and intravenous anticancer drugs, reducing patient out-of-pocket cost barriers for oral treatments.
Who must act
Group health plans and health insurance issuers offering coverage for anticancer medications administered by a health care provider.
What happens
Lower patient cost-sharing for oral anticancer drugs increases patient adherence and prescription fill rates, expanding the addressable patient population for oral oncology products.
Stock impact
Merck's oncology portfolio includes oral drugs such as Lynparza (olaparib, partnered with AstraZeneca) and vorinostat; increased uptake of oral oncolytics directly boosts prescription volumes and revenue from these products.
What the bill does
Mandate for group health plans to equalize cost-sharing between oral and intravenous anticancer drugs, reducing patient out-of-pocket cost barriers for oral treatments.
Who must act
Group health plans and health insurance issuers offering coverage for anticancer medications administered by a health care provider.
What happens
Lower patient cost-sharing for oral anticancer drugs increases patient adherence and prescription fill rates, expanding the addressable patient population for oral oncology products.
Stock impact
Eli Lilly's oncology pipeline includes oral targeted therapies such as LOXO-305 (pirtobrutinib, BTK inhibitor) and potential future oral oncology candidates; parity provisions support uptake of oral drugs relative to infusions.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Benay Taub Lung Cancer Research Act
American Innovation and R&D Competitiveness Act of 2025
Most Favored Patient Act of 2026
Lowering Drug Costs for American Families Act
Protecting Americans from Unsafe Drugs Act of 2026
ABC Safe Drug Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.